Home › All Companies › ATYR

aTYR PHARMA INC (ATYR)

AI-Powered SEC Filing Analysis

Current Report Filed: 2026-03-05

Key Insights

  • aTyr Pharma reported its full-year 2025 financial results, providing investors with an update on the company's operational and financial performance.
  • The company did not provide any forward-looking guidance or commentary on future product development or regulatory milestones, which could be a concern for investors looking for visibility into the company's pipeline and growth prospects.
  • The lack of any major business updates or news in this 8-K filing suggests the company may be in a relatively stable, ongoing operational phase without significant near-term catalysts.
Sentiment: Neutral Significance: 4/10
View Original Filing →
Annual Report Filed: 2026-03-05

Key Insights

  • aTYR PHARMA INC reported a significant increase in license and collaboration revenues in 2025, likely driven by its partnership with Kyorin Pharmaceutical Co Ltd.
  • The company's balance sheet remains strong, with a substantial amount of short-term investments and commercial paper holdings as of the end of 2025.
  • aTYR PHARMA continues to invest heavily in research and development, with R&D expenses increasing year-over-year, which may impact the company's profitability in the near term.
Sentiment: Positive Significance: 6/10
View Original Filing →
Insider Trading Filed: 2026-01-09

Key Insights

  • The reporting person, Nancy Denyes, acquired 31,555 shares of aTYR PHARMA INC (ATYR) common stock through the company's 2015 Employee Purchase Plan in multiple transactions.
  • Denyes was granted a stock option to purchase 412,500 shares of ATYR common stock at an exercise price of $0.7127 per share, which will vest in 36 equal monthly installments starting February 9, 2026.
  • The stock option is subject to accelerated vesting upon termination without cause upon a change of control of the issuer, providing an incentive for Denyes to remain with the company during a potential acquisition.
Sentiment: Positive Significance: 6/10
View Original Filing →

Get real-time filing analysis in the app

Download on the App Store

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.